Table 5 Outcomes and hazard ratios for FDAF patients stratified by electrical vs. pharmacological cardioversion
Variables | Electrical CV n = 576 | Pharmacological CV n = 103 | p-value |
|---|---|---|---|
All-cause mortality, n(%all) | 53 (9.2) | 21 (20.4) | 0.0008 |
HR (95%CI) |  | 3.61 (1.85–7.04) | 0.0002 |
Cardiac-death*, n(%all) | 13 (2.3) | 8 (7.8) |  < 0.0001 |
HR (95%CI) |  | 8.03 (2.3–27.6) | 0.0001 |
Non-cardiac death, n(%all) | 40 (6.9) | 13 (12.6) |  < 0.0001 |
HR (95%CI) |  | 2.62 (1.19–5.78) | 0.0172 |
Stroke, n(%all) | 13 (2.5) | 4 (4.3) | 0.3183 |
HR (95%CI) |  | 2.38 (0.59–9.58) | 0.2231 |
Major bleeding, n(%all) | 24 (4.6) | 1 (1.1) | 0.1156 |
HR (95%CI) |  | 0.45 (0.14–1.46) | 0.1824 |
Myocardial infarction, n(%all) | 12 (2.3) | 3 (3.2) | 0.5854 |
HR (95%CI) |  | 1.70 (0.39–7.42) | 0.4785 |